Clinical and Biochemical Assessment of the Effect of Topical Use of Coenzyme Q10 Versus Topical Corticosteroid in Management of Symptomatic Oral Lichen Planus: Randomized Controlled Clinical Trial
Oral Lichen Planus
About this trial
This is an interventional treatment trial for Oral Lichen Planus focused on measuring co enzymeQ10 - Antioxidant- Corticosteroids
Eligibility Criteria
Inclusion Criteria:
- Patients free from any systemic disease according to the detailed questionnaire of the modified Cornell Medical Index 34.
- Patients not receiving any medication either topical or systemic that could cause lichenoid reaction during the 3 months before the study.
- Patients diagnosed by a dermatologist and oral medicine specialist as suffering from OLP.
- Patients clinically and histopathologically diagnosed as suffering from OLP according to World Health Organization's (WHO's) clinic-pathological diagnostic criteria for LP35.
- Patients who agree for the biopsy in undiagnosed cases.
Patients who are willing to participate in this study (will give informed consent) and have the ability to complete the study.
- Exclusion criteria:
(1) Patients taking systemic drugs such as systemic steroid, other immunosuppressive therapy for at least 8 weeks prior to the study.
(2) Patients treated with any oral topical medications for at least four weeks prior to the study.
(3) Patients with suspected restoration-related reaction. (4) Pregnant and lactating mothers.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
topical Q10 mucoadhesive tablets
topical corticosteroid
will receive topical co enzyme q10 in the form of mucoadhesive tablets 3 times daily for 3months.
will receive topical corticosteroid (kenacort A Orabase: triamcinolone acetonide 0.1%5gram adhesive paste - dermapharm), 4 times daily for 3months.